Neopharm   Report issue

For profit Phase 2
Founded: Blainville Canada (1990)
Status: Acquired by Insys Therapeutics Inc (2010)

Organization Overview

First Clinical Trial
2018
NCT03406611
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Neopharm Bulgaria Ltd. | Orphan Technologies Ltd

Active Ingredients

Drugs in Phase 2 Trials (2)

ee-tp (1 trial)

ot-58 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Homocystinuria (Phase 2)

Metabolic Diseases (Phase 2)

Metabolism, Inborn Errors (Phase 2)

Mitochondrial Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2